Compounded Tirzepatide: Legality, Safety, Cost, Providers
The FDA has not approved compounded tirzepatide.
- Active ingredient
- tirzepatide
- FDA status
- Compounded copies are not FDA approved
Zepbound at a glance
Half-life 5 to 6 days: half is gone after 5.5 d, and about 3% is left after five half-lives (27.5 d).
SURMOUNT-1, 72 weeks: 20.9% of body weight against 3.1% on placebo.
Monthly price points in US dollars: list price and self-pay offers, each read from the maker's price page.
Sources: FDA label (DailyMed), Eli Lilly 1 2, cnbc.com.
Since early 2025, pharmacies face much tighter limits on making copies of it than they did while the drug was in shortage. Eli Lilly sells the brand-name medicine, Zepbound, directly, and self-pay prices start at 299 USD each month.
Is it still legal?
In compounding, a pharmacy prepares its own version of a drug rather than selling the factory-made version. While tirzepatide sat on the FDA shortage list, pharmacies could make it. The drug first appeared on the list on 15 December 2022, and the FDA declared the shortage resolved on 19 December 2024.
Compounders fall into two groups. Local pharmacies that fill single prescriptions had a deadline of 18 February 2025. Larger outsourcing facilities had a later deadline, 19 March 2025. Local pharmacies also face limits on making products that are essentially copies of an approved medicine.
The restrictions have grown stricter over time. On 6 February 2026, the FDA announced its plan to take action against GLP-1 drugs that lack FDA approval. Then, on 30 April 2026, it put forward a proposal to keep tirzepatide off the list of raw ingredients outsourcing facilities can use. The public comment period ends on 29 June 2026.
Safety and side effects
By 31 May 2026, the FDA had received more than 730 reports of people having problems after using unapproved tirzepatide products. These reports don't prove the drug caused each problem, but they are one reason the FDA urges caution. Since the FDA never approved these products, nobody has confirmed that they are safe, effective, or made to a consistent standard.
Some compounders rely on "salt forms" of the drug. Chemically, they differ from the ingredient used in the approved medicine, and the FDA has raised concerns about these forms.
Telehealth companies
During the shortage, plenty of online clinics offered compounded tirzepatide. The FDA has issued 30 warning letters to telehealth companies about the illegal marketing of compounded GLP-1 drugs. Such a letter is a formal FDA notice that a company is breaking the rules. Among the issues the FDA highlighted was marketing that implies approval for products that have none.
Results
No FDA-reviewed results exist for compounded tirzepatide, since the drug never went through the approval process. The Zepbound and Mounjaro labels list results drawn from studies of the brand-name medicines, not from any version produced by a pharmacy.
Will it work as well for weight loss?
Online claims about weight loss from compounded products cannot be compared with results for the brand-name drug. The FDA has not reviewed what these products contain, so their ingredient and dose may differ from what researchers studied.
Before and after photos
Clinic websites use before and after photos to promote their services. The FDA has not reviewed these images, and the product pictured might not match what you would actually get.
What to do if it is not working
Because compounded versions aren't approved, there are no official instructions for what to do if one doesn't seem to help. A compounded version might contain a salt form or a different strength than the approved medicine. Talking with your doctor is a good first step. They can help you work out whether an approved medicine, with a clearly labeled dose, might suit you better.
Cost of brand-name tirzepatide
Zepbound is sold directly by Eli Lilly through LillyDirect. The listed prices cover one month and apply for people paying on their own.
| Dose | Monthly cost when refilled within 45 days | Usual monthly cost |
|---|---|---|
| 2.5 mg | 299 USD per month | 299 USD per month |
| 5 mg | 399 USD per month | 399 USD per month |
| 7.5 mg | 449 USD per month | 499 USD per month |
| 10 to 15 mg | 449 USD per month | 699 USD per month |
A Zepbound vial is also listed on TrumpRx starting at 299 USD per month.
Questions people often ask
How does compounded tirzepatide compare with regular tirzepatide?
The FDA has reviewed the brand-name medicines Mounjaro, approved in 2022 for type 2 diabetes, and Zepbound, approved in 2023 for weight management. No such review exists for compounded versions, so there is no evidence showing they perform as well.
Where can I get tirzepatide legally?
The approved medicine is available with a prescription. Options include self-pay through LillyDirect or TrumpRx. Both Mounjaro and Zepbound are marketed by Eli Lilly.